近日，因公司业务调整，甘李药业股份有限公司（以下简称"公司"）董事 会召开第五届董事会第六次会议，审议通过了《关于解聘高级管理人员的议案》 《关于指定周丽女士代行财务负责人职责的议案》，现将相关情况公告如下： 一、高级管理人员离任情况 (一) 提前离任的基本情况 证券代码：603087 证券简称：甘李药业 公告编号：2026-002 甘李药业股份有限公司 关于公司解聘高级管理人员及指定人员代行财务负 责人职责的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、指定人员代行财务负责人职责情况 为确保公司的日常运作及财务管理工作的平稳有序开展，在董事会聘任新财 务负责人之前，经公司提名委员会、审计委员会审议通过，董事会同意指定公司 周丽女士代行公司财务负责人职责。公司将尽快根据相关法律法规的规定聘任财 务负责人，并及时履行相关信息披露义务。 三、审计委员会的意见 公司于 2025 年 12 月 31 日召开第五届董事会审计委员会第三次会议，审议 通过了《关于解聘高级管理人员的议案》《关于指定周丽女士代行财务负责人职 责的议 ...

Core Viewpoint - The biopharmaceutical sector experienced a slight decline of 0.34% on December 30, with Wanze Co., Ltd. leading the losses. The Shanghai Composite Index closed at 3965.12, down 0.0%, while the Shenzhen Component Index rose by 0.49% to 13604.07 [1]. Group 1: Market Performance - The biopharmaceutical sector's performance showed mixed results, with individual stocks experiencing varying degrees of gains and losses. Notably, Aidi Pharmaceutical saw a rise of 4.10% to close at 15.98, while Wanze Co., Ltd. fell by 6.76% to 21.94 [1][2]. - The trading volume for Aidi Pharmaceutical was 93,900 shares, with a transaction value of 150 million yuan, indicating strong investor interest [1]. Group 2: Capital Flow - The biopharmaceutical sector faced a net outflow of 330 million yuan from institutional investors, while retail investors contributed a net inflow of 349 million yuan, suggesting a shift in investor sentiment [2]. - The data indicates that while institutional investors withdrew funds, retail investors were more active in purchasing shares within the sector [2][3]. Group 3: Individual Stock Analysis - Ganne Pharmaceutical experienced a net outflow of 34.73 million yuan from institutional investors, while retail investors showed a net inflow of 129.36 million yuan, reflecting a divergence in investment strategies [3]. - Other notable stocks included Huashan Biological, which had a net inflow of 430.99 million yuan from institutional investors, indicating positive sentiment towards its performance [3].

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688293 | 奧浦迈 | 49.23 | -5.91% | 1.46万 | 7313.40万 | | 300357 | 我武生物 | 28.23 | -3.42% | 8.14万 | 2.32 Z | | 002581 | ST未名 | 7.36 | -3.41% | 5.71万 | 4244.92万 | | 603087 | 甘李药业 | 66.15 | -3.13% | 1 8.20万 | 5.48亿 | | 002773 | 康弘药业 | 29.85 | -2.96% | 6.82万 | 2.05亿 | | 688670 | 金過完 | 21.25 | -2.88% | 2.79万 | 5955.49万 | | 000534 | 万泽股份 | 23.53 | -2.85% | 13.98万 | 3.31亿 | | 300841 | 康华生物 | 72.66 | -2.85% | 2.29万 | 1.68亿 | | 920047 | 诺思兰 ...

Investment Rating - The report suggests a positive investment outlook for the medical device sector, particularly in brain-computer interface devices, which are expected to see accelerated commercialization due to supportive policies [1][3]. Core Insights - Recent policies have significantly increased support for innovation in medical devices, with the National Medical Products Administration actively promoting faster market entry for brain-computer interface devices, indicating a diverse application landscape and substantial future potential [1][3]. - The pharmaceutical sector is witnessing positive developments, such as GSK's approval of mepolizumab for a new indication in COPD patients, marking it as the first monthly administered biologic in China, which is expected to reduce the annual incidence of severe exacerbations significantly [1][32]. - The report highlights the approval of Wegovy® tablets in the U.S. for weight management, emphasizing its potential impact on the market as the first oral GLP-1 receptor agonist for this purpose [37][40]. Summary by Sections Pharmaceutical Sector - Mepolizumab has been approved for COPD treatment in China, with a monthly dosing schedule, targeting a significant patient population [1][32]. - The A/H share innovation drug sector maintains high activity levels, with new drug approvals and cross-border transactions remaining robust [16][28]. Biologics - Wegovy® tablets have been approved in the U.S. for weight management, showing similar weight loss efficacy to its injectable counterpart, with a significant portion of participants achieving substantial weight loss [37][40]. CXO and Pharmaceutical Supply Chain - The CXO sector continues to show upward momentum, supported by a stable order backlog, with November financing levels slightly above the annual average [44][46]. Medical Devices - The centralized procurement process for high-value medical consumables is progressing steadily, with high selection rates in multiple rounds of bidding, indicating a favorable environment for leading domestic companies [2][52]. Retail Pharmacy - The industry is undergoing a consolidation phase, with leading companies expected to benefit from increased market share through mergers and acquisitions [2][3]. Medical Services and Consumer Healthcare - Aier Eye Hospital's acquisition of 39 institutions for 960 million yuan strengthens its market position, with the acquired entities showing signs of financial recovery [2][3].

Core Viewpoint - Ganli Pharmaceutical (603087) is currently conducting clinical trials for the injection of Bofan Glutide, and the commercial revenue generated will depend on the success and progress of subsequent research, registration, and market introduction of the product [1] Group 1 - The company is actively engaging with investors through an interactive platform [1] - The specific revenue from the product will be contingent on future developments in research and market strategies [1] - The company commits to timely information disclosure regarding important advancements in drug trials and commercialization [1]

Core Viewpoint - Ganli Pharmaceutical has granted exclusive rights to develop and commercialize the injection of Bofan Glutide in Latin America, including key countries like Mexico and Brazil, to PC, marking a new commercial strategy for Ganli's innovative drug in the region [1] Group 1 - Ganli Pharmaceutical confirmed that the Bofan Glutide injection is still in clinical trials, and the specific revenue from commercialization will depend on the success and progress of subsequent research, registration, and market introduction [1] - The company will fulfill its information disclosure obligations regarding future drug trial arrangements and significant commercial progress [1]

Core Viewpoint - The event highlighted the commitment of Lunan Pharmaceutical Group to social welfare and health, showcasing its strategic focus on chemical, traditional Chinese, and biopharmaceuticals while promoting regional industrial upgrades [1] Group 1: Event Overview - The Linyi Modern Pharmaceutical Industry High-Quality Development Matchmaking Conference was held on December 19, featuring over 140 enterprises and nearly 1,000 attendees from various sectors including pharmaceuticals, medical devices, and health products [1] - Lunan Pharmaceutical has been rooted in Linyi for 58 years, emphasizing its mission to benefit society and improve quality of life [1] Group 2: Company Strategy and Products - Lunan Pharmaceutical showcased its product strategy focusing on maintaining advantages in chemical pharmaceuticals, significantly developing traditional Chinese medicine, and strengthening biopharmaceuticals [1] - The company presented successful products such as Qidali Jingfang Granules, reflecting its comprehensive strength and innovative vitality in the health sector [1] Group 3: Support and Collaboration - The event featured a policy consultation area where local government departments provided one-stop services to support enterprises in policy applications and resource connections [1] - Representatives from 10 companies, including Lunan Pharmaceutical and others, delivered promotional speeches, indicating a collaborative effort to enhance the pharmaceutical industry [1]

Core Viewpoint - On December 22, a total of 18 listed companies will have their restricted shares unlocked, with a total market value of approximately 102.97 billion yuan [1] Group 1: Unlocking Details - Walton Technology (Stock Code: 000920) will unlock 50.62 million shares from a private placement of A-shares [1] - China Hengtian Group (Stock Code: 600252) will unlock 2.36 million shares from equity incentive restrictions [1] - Huadian Energy (Stock Code: 600726) will unlock 4.73 billion shares from a private placement of A-shares [1] - AVIC Heavy Machinery (Stock Code: 600765) will unlock 2.68 million shares from equity incentive restrictions [1] - Nanjing Port (Stock Code: 002040) will unlock 151,800 shares from equity incentive restrictions [1] - Weichai Power (Stock Code: 000338) will unlock 23.48 million shares from equity incentive restrictions [1] - First Capital Securities (Stock Code: 601136) will unlock 2.25 billion shares from pre-issue share restrictions [1] - Anke Technology (Stock Code: 300370) will unlock 237 million shares from other restrictions [1] - Xinya Process (Stock Code: 002388) will unlock 346,550 shares from equity incentive restrictions [1] - Zhaoyi Innovation (Stock Code: 603986) will unlock 64,600 shares from equity incentive restrictions [1] - Ganli Pharmaceutical (Stock Code: 603087) will unlock 164,530 shares from equity incentive restrictions [1] - Yaxiang Co., Ltd. (Stock Code: 301220) will unlock 33.39 million shares with an extended lock-up period [1] - Mousse Co., Ltd. (Stock Code: 001323) will unlock 300 million shares with an extended lock-up period [1] - Sany Heavy Energy (Stock Code: 688349) will unlock 942 million shares [1] - Southern Power Technology (Stock Code: 688248) will unlock 336 million shares [1] - Jingwei Hengrun (Stock Code: 688326) will unlock 118,400 shares [1] - Kangwei Century (Stock Code: 688426) will unlock 434,200 shares [1] - Yuanjie Technology (Stock Code: 688498) will unlock 23.85 million shares [1]

Core Viewpoint - Gannee Pharmaceutical experienced a stock price decline of 2.02% on December 18, with a current price of 65.45 CNY per share and a total market capitalization of 39.094 billion CNY. The company has seen a year-to-date stock price increase of 51.84% [1] Financial Performance - For the period from January to September 2025, Gannee Pharmaceutical reported a revenue of 3.047 billion CNY, representing a year-on-year growth of 35.73%. The net profit attributable to shareholders was 818 million CNY, reflecting a year-on-year increase of 61.32% [2] Shareholder Information - As of September 30, 2025, the number of shareholders for Gannee Pharmaceutical reached 94,700, an increase of 22.53% from the previous period. The average number of circulating shares per shareholder decreased by 17.81% to 5,889 shares [2] Dividend Distribution - Since its A-share listing, Gannee Pharmaceutical has distributed a total of 1.612 billion CNY in dividends, with 1.018 billion CNY distributed over the past three years [3] Major Shareholders - As of September 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited as the third-largest shareholder with 8.0042 million shares, an increase of 494,300 shares from the previous period. Other notable shareholders include Southern CSI 500 ETF and China Merchants National Bio-pharmaceutical Index A, with varying changes in their holdings [3]

Core Viewpoint - The biopharmaceutical sector experienced a rise of 0.76% on December 17, with ST Weiming leading the gains. The Shanghai Composite Index closed at 3870.28, up 1.19%, while the Shenzhen Component Index closed at 13224.51, up 2.4% [1]. Group 1: Stock Performance - ST Weiming (002581) closed at 7.49, with a gain of 5.05% and a trading volume of 58,400 shares, amounting to a transaction value of 43.46 million yuan [1]. - Wendi Pharmaceutical (688488) closed at 14.59, up 4.36%, with a trading volume of 56,400 shares and a transaction value of 80.52 million yuan [1]. - Kanghua Biological (300841) closed at 75.75, increasing by 2.98%, with a trading volume of 13,700 shares and a transaction value of 102 million yuan [1]. - Wan Ze Co., Ltd. (000534) closed at 23.31, up 2.24%, with a trading volume of 226,800 shares and a transaction value of 519 million yuan [1]. - Other notable stocks include Kang Le Wei Shi (920575) at 10.28 (+1.88%), Gan Li Pharmaceutical (603087) at 66.80 (+1.71%), and Anke Biological (300009) at 9.67 (+1.58%) [1]. Group 2: Capital Flow - The biopharmaceutical sector saw a net outflow of 344 million yuan from institutional investors, while retail investors experienced a net inflow of 441 million yuan [2]. - The capital flow for ST Weiming showed a net inflow of 14.06 million yuan from institutional investors, while retail investors had a net outflow of 645.75 million yuan [3]. - Kanghua Biological had a net inflow of 13.85 million yuan from institutional investors, with retail investors also experiencing a net outflow of 625.92 million yuan [3].